Publicaciones en las que colabora con Pilar Sánchez Gómez (14)

2022

  1. Blood-Brain Barrier Disruption: A Common Driver of Central Nervous System Diseases

    Neuroscientist, Vol. 28, Núm. 3, pp. 222-237

2021

  1. Tumor-derived pericytes driven by egfr mutations govern the vascular and immune microenvironment of gliomas

    Cancer Research, Vol. 81, Núm. 8, pp. 2142-2156

2020

  1. Immune profiling of gliomas reveals a connection with IDH1/2 mutations, tau function and the vascular phenotype

    Cancers, Vol. 12, Núm. 11, pp. 1-18

  2. Phase II Trial of Palbociclib in Recurrent Retinoblastoma-Positive Anaplastic Oligodendroglioma: A Study from the Spanish Group for Research in Neuro-Oncology (GEINO)

    Targeted Oncology, Vol. 15, Núm. 5, pp. 613-622

  3. The EGFR-TMEM167A-p53 axis defines the aggressiveness of gliomas

    Cancers, Vol. 12, Núm. 1

  4. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas

    Science Translational Medicine, Vol. 12, Núm. 527

2019

  1. Correlation of radiological and immunochemical parameters with clinical outcome in patients with recurrent glioblastoma treated with Bevacizumab

    Clinical and Translational Oncology, Vol. 21, Núm. 10, pp. 1413-1423

  2. NFATc3 controls tumour growth by regulating proliferation and migration of human astroglioma cells

    Scientific Reports, Vol. 9, Núm. 1

  3. Ocoxin Modulates Cancer Stem Cells and M2 Macrophage Polarization in Glioblastoma

    Oxidative medicine and cellular longevity, Vol. 2019, pp. 9719730

2017

  1. Glioblastoma on a microfluidic chip: Generating pseudopalisades and enhancing aggressiveness through blood vessel obstruction events

    Neuro-Oncology, Vol. 19, Núm. 4, pp. 503-513

  2. Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification

    Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531

2015

  1. Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma

    Oncotarget, Vol. 6, Núm. 13, pp. 10950-10963

  2. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma

    Molecular Cancer Therapeutics, Vol. 14, Núm. 7, pp. 1548-1558

2013

  1. Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth

    Journal of Clinical Investigation, Vol. 123, Núm. 6, pp. 2475-2487